IBD: Ulcerative Colitis
IBD: Switching from a Biologic to a Biosimilar
Updated March 20201
Having to change any kind of medication can be very stressful. While CDHF believes in patient-physician choice, we acknowledge political policy decisions and our organization is committed to providing clear and unbiased information and resources for patients. Both biologics and biosimilars have gone through rigorous standards for authorization by Health Canada, to which both have been found safe and effective for use in Inflammatory Bowel Disease (IBD). Watch this video to learn more about switching from a biologic to a biosimilar.
Related Articles
Treating Crohn’s Disease Although several drugs are useful in controlling these conditions, as yet a cure has not been found. Since the disease is not curable, […]
Updated March 2021 Having to change any kind of medication can be very stressful. While CDHF believes in patient-physician choice, we acknowledge political policy decisions and […]
Patient Survey BC PharmaCare and Alberta Health coverage is changing for people who take Remicade® (infliximab) for the treatment of Crohn’s disease or ulcerative colitis. In […]